ScholarLens Back to search
2014•OncoImmunologyOpen access

Novel insights into the mechanism of action of lenalidomide

Michaëla Semeraro, Lorenzo Galluzzi

Open full text 19 citations

Abstract

Lenalidomide (Revlimid®) is a synthetic derivative of thalidomide (Thalomid®) currently licensed by the US Food and Drug Administration (FDA) and other international regulatory agencies for the tre...

About this research paper

What this paper is about

Lenalidomide (Revlimid®) is a synthetic derivative of thalidomide (Thalomid®) currently licensed by the US Food and Drug Administration (FDA) and other international regulatory agencies for the tre...

Why it matters

OpenAlex reports 19 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Lenalidomide (Revlimid®) is a synthetic derivative of thalidomide (Thalomid®) currently licensed by the US Food and Drug Administration (FDA) and other international regulatory agencies for the tre...

Key concepts: Lenalidomide, Thalidomide, Pomalidomide, Multiple myeloma, Medicine, Cereblon, Dexamethasone, Pharmacology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Novel insights into the mechanism of action of lenalidomide — Research Paper | ScholarLens